JPMorgan Chase & Co. Raises Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

JPMorgan Chase & Co. lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 159.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 554,835 shares of the specialty pharmaceutical company's stock after acquiring an additional 340,854 shares during the quarter. JPMorgan Chase & Co. owned approximately 2.64% of ANI Pharmaceuticals worth $33,101,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ANIP. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after purchasing an additional 579 shares during the last quarter. XTX Topco Ltd acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth about $207,000. HighTower Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at about $222,000. Profund Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $225,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $228,000. Institutional investors own 76.05% of the company's stock.

Insider Buying and Selling

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the firm's stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,231 shares of company stock worth $2,434,286 in the last quarter. Insiders own 12.70% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ANIP. Leerink Partnrs raised shares of ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Truist Financial raised their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research note on Tuesday, October 22nd. Finally, Piper Sandler initiated coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an "overweight" rating and a $68.00 price target on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, ANI Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $77.71.

ANI Pharmaceuticals Stock Down 0.4 %

ANI Pharmaceuticals stock traded down $0.22 during mid-day trading on Tuesday, reaching $54.38. The stock had a trading volume of 181,595 shares, compared to its average volume of 151,024. The firm has a market capitalization of $1.14 billion, a PE ratio of -98.87 and a beta of 0.73. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The stock's 50-day simple moving average is $56.79 and its 200-day simple moving average is $59.23. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same quarter last year, the firm posted $1.05 EPS. ANI Pharmaceuticals's revenue was up 12.5% compared to the same quarter last year. On average, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.